New Claims Monitoring Policy for EPO/Aranesp
About Craneware Insights
Craneware Insights Articles communicate important regulatory changes to Medicare Outpatient billing, Chargemaster (CDM) and coding compliance. Craneware analyzes Transmittals and bulletins from the Centers for Medicare and Medicaid Services (CMS) and other organizations such as Recovery Audit Contractors (RACs) and emails Insights Articles in a focused manner to alert customers to pertinent regulatory changes.
Regulatory News Topic
Change Request (?CR?) 4135 released November 10, 2005, announces a new national monitoring policy for erythropoietin and darbepoetin (EPO and Aranesp) for ESRD patients treated in renal dialysis facilities. The intent of this policy is to ensure that EPO and Aranesp are not over-utilized in the treatment of the Medicare ESRD in-facility population.
Date of Insight Article
Friday, November 11, 2005
What you need to know and action needed
To view this complete Insights Article including detailed breakdown of Provider Types Affected, Departments Affected, What You Need to Know, Action Needed and Background and Reference links, customers may sign onto Craneware Online Reference Toolkit?.